Ptc Therapeutics (PTCT) Operating Leases (2019 - 2025)
Historic Operating Leases for Ptc Therapeutics (PTCT) over the last 7 years, with Q3 2025 value amounting to $107.3 million.
- Ptc Therapeutics' Operating Leases rose 1075.01% to $107.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 1075.01%. This contributed to the annual value of $74.9 million for FY2024, which is 2323.13% down from last year.
- As of Q3 2025, Ptc Therapeutics' Operating Leases stood at $107.3 million, which was up 1075.01% from $83.0 million recorded in Q2 2025.
- Ptc Therapeutics' Operating Leases' 5-year high stood at $146.3 million during Q2 2022, with a 5-year trough of $73.6 million in Q4 2021.
- Its 5-year average for Operating Leases is $96.3 million, with a median of $96.9 million in 2024.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 9136.54% in 2022, then tumbled by 2879.68% in 2025.
- Ptc Therapeutics' Operating Leases (Quarter) stood at $73.6 million in 2021, then surged by 37.0% to $100.9 million in 2022, then decreased by 3.21% to $97.6 million in 2023, then fell by 23.23% to $74.9 million in 2024, then surged by 43.17% to $107.3 million in 2025.
- Its Operating Leases stands at $107.3 million for Q3 2025, versus $83.0 million for Q2 2025 and $85.0 million for Q1 2025.